Wepreviously reported that oxanosine as well as 5-FU, among various compounds tested, inhibited growth in vitro of \-K-ras NRK(ras+) cells more strongly than inhibited that of cells1}.
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IC50 of oxanosine for ras+ and ras~cells was 4.9 jUg/mla and >40^g/ml13, respectively (b/a for oxanosine= >8), while those of 5-FU were 0.036 fig/m\a and 0.17^g/mlb, respectively (b/a for 5-FU=4.6). Another pair ofras+ cells and ras~cells, i.e., K-ras NIH/3T3 and NIH/3T3, respectively, gave a similar result. The effect of the two drugs in combination2* on ras+ cells was synergistic as shown in Fig. 1 parallel. As shown in Fig. 2 , the differential effect of 5-FU on ras+ cells was far greater in the 2-hour-exposure experiment (IC50 for ras+ and ras~w ere 0.35/jg/mla and 4.7iug/mlb; b/a= 13) than in the 48-hour-exposure experiment. A prior 2-hourexposure of ras+ cells to lO jUg/ml oxanosine, which on its own had no effect on cell growth, significantly enhanced the effect of subsequent 2-hour-exposure to 5-FU (Table 1 , Schedule A). In contrast, there was only weak enhancement with nontumorous control cells (NIH/3T3) and with tumorous cells in which another oncogene, src, was expressed (src NIH/3T3). Furthermore, the order of exposure to the two drugs was an important factor to make An NIH/3T3 cell line transformed with a humanactivated c-K-ras gene carrying a point mutation at codon 12 (K-ra.s NIH/3T3) was provided by Dr. T. Sekiya, National Cancer Center Research Institute, Tokyo. Culture conditions were as reported3). In figures A and B, the isoboles equivalent to 36%and 62% relative growth (vs. each control) are shown, respectively. Cells and culture conditions were as reported3). Coster 12-well tissue culture clusters (4cm2/well) were used as culture vessels. In each vessel, 1~2 x 104 cells were seeded in 2ml medium(day 0). Effects ofa drug on cell growth were determined by two protocols. (1) Cells received a drug on day 1 and were further cultured until day 3 without changing the medium (a 48-hour-exposure: A, A). (2) On day 1, cells were exposed to a drug for 2 hours, washed free of the drug with 1ml of Ca2+-and Mg2+-free PBS, and further cultured in the ordinary medium until day 4 (a 2-hour-exposure: à", O). An NIH/3T3cell line transformed with a human activated c-H-ras gene carrying a point mutation at codon 61 (U-ras NIH/3T3) was provided by Dr. T. Sekiya, National Cancer Center Research Institute, Tokyo4). Other cell lines and culture conditions were as reported3). Cells were seeded as described in the legend to Fig. 2 . On day 1, cells were exposed to a drug (or two drugs simultaneously, Schedule B) for 2 hours, washed free of the drug with 1ml of Ca2+-and Mg2+-free PBS and, in Schedule A and C, the cells were exposed to a second drug for 2 hours, washed and further cultured in the ordinary medium until day 4 (a 2-hour-exposure).
Experiments A, B and C were conducted separately. Runs were duplicated. the ras+ specific enhancementeffective; no enhancement at all if the order was reversed (Schedule C), while only moderate enhancement if the two drugs were present simultaneously (Schedule B).
Weexamined if the synergism so far shown in vitro between 5-FU and oxanosine could be reflected in inhibiting growth of ras+ tumors in mice. As shown in Fig. 3 , the combination of oxanosine and 5-FU significantly decreased the progression of tumors as long as the treatment continued (day 6 K-rasNIH/3T3 cells (107 cells/0.5 ml medium) were injected sc to a 6-week-old female Balb/c-nuA mouse (Clea Japan Inc.). In two weeks the mouse developed a tumor, 1 cm in diameter. The tumor was excised and cut into about 1 mm3fragments and each fragment was inoculated sc to another mouse (day 0). Each determination was made with 5 mice (n=5). On day 6 to 10, oxanosine (sc) and 4 hours later 5-FU (iv) were administered. The effect of each drug alone was also tested. With each tumor, the largest diameter (L) and its perpendicular diameter (W) were measured and the volume was calculated as 1/2-L-W2. The unit (1.0) of "relative tumor volume" was equivalent to 134mm3. to 10), but failed to induce any significant tumor regression. Studies on the molecular mechanism underlying the synergistic effect is in progress. More stable guanosine analogs maygive better results.
